Lumos Diagnostics Holdings (ASX:LDX) Debt-to-Asset : 0.37 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Debt-to-Asset?

Lumos Diagnostics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.35 Mil. Lumos Diagnostics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$11.39 Mil. Lumos Diagnostics Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$34.44 Mil. Lumos Diagnostics Holdings's debt to asset for the quarter that ended in Dec. 2023 was 0.37.

Lumos Diagnostics Holdings Debt-to-Asset Historical Data

The historical data trend for Lumos Diagnostics Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Debt-to-Asset Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

Debt-to-Asset

0.20

0.39

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial			0.13	0.20	0.19	0.39	0.37

Competitive Comparison of Lumos Diagnostics Holdings's Debt-to-Asset

For the Diagnostics & Research subindustry, Lumos Diagnostics Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumos Diagnostics Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Debt-to-Asset falls into.

Lumos Diagnostics Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lumos Diagnostics Holdings's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.037	+	11.543)	/	37.874
	=	0.38

Lumos Diagnostics Holdings's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.354	+	11.386)	/	34.44
	=	0.37

Lumos Diagnostics Holdings (ASX:LDX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Lumos Diagnostics Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines